LMAT - LeMaitre Vascular, Inc.
BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
I don't love valuation models because they rely on assumptions, and assumptions can be dangerous. But we still need to pay attention. I sold my position in BIPC not because I don't like the stock or that I'm spooked by recent movement, but rather in the optic of portfolio simplification. Since I started this portfolio in September 2017, I have received a total of $36,444.54 CAD in dividends.
CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.
LeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
BURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
LeMaitre (LMAT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
BURLINGTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT) announced today that management will present at the Bank of America Healthcare Conference on Wednesday, May 13, 2026, at 5:15 PM PT.
LeMaitre (LMAT) is well positioned to outperform the market, as it exhibits above-average growth in financials.
LeMaitre (LMAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LeMaitre Vascular, Inc. (LMAT) Q1 2026 Earnings Call Transcript
LeMaitre Vascular (LMAT) came out with quarterly earnings of $0.68 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.48 per share a year ago.
BURLINGTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q1 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
Comerica Bank trimmed its position in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 6.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 133,243 shares of the medical instruments supplier's stock after selling 9,589 shares during the quarter. Comerica Bank owned 0.59% of
After 3 months in 2026, I heard more noise than quality information. Therefore, I don't intend to make any modifications to my portfolio at this point. Dollarama reported a mixed quarter with revenue up 12%, but EPS was up only 2%. That sent the stock price down and created the temptation to invest a little more in this amazing company. I'm accumulating more dividends in this portfolio, and I'll shortly have another $1,000 to invest! I will likely add more of Broadcom as I'm not yet fully invested at 3% of the portfolio in this security.
BURLINGTON, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
BURLINGTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2025, at 2:15 PM EDT.
Shares of LeMaitre Vascular, Inc. (NASDAQ: LMAT - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average
2,625 shares were exercised and sold on March 11, 2026, generating a transaction value of approximately $285,000 at a weighted average sale price of around $108.50 per share. This disposition represented 28.22% of Kamke's direct holdings prior to the transaction, reducing direct ownership to 6,677 shares.
An executive of LeMaitre Vascular reported selling 2,625 shares of the company for $285,000 on March 11, 2026. The sale represented 28.22% of Kamke's direct common stock holdings, reducing the position to 6,677 shares.
Congress Asset Management Co. boosted its stake in LeMaitre Vascular, Inc. (NASDAQ: LMAT) by 5.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 732,331 shares of the medical instruments supplier's stock after acquiring an additional 40,065 shares during the quarter. Congress Asset Management Co.